Corneal Endothelial Cell Loss

3

Review clinical trials related to Corneal Endothelial Cell Loss. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery

This study is designed to assess whether an investigational eye drop called CA201A can help protect the cornea (the outer covering of the eye) and reduce damage to corneal endothelial cells following cataract surgery, without causing significant side effects. Cataract surgery is one of the common surgical procedures, however, it can sometimes lead to a loss of corneal endothelial cells, which are essential for maintaining the corneal clarity and long-term eye health. About 200 adults in Australia who are scheduled to have cataract surgery will be enrolled in this study following eligibility check. All eligible participants will be randomly assigned (by chance) to receive either the CA201A eye drops or a similar eye drop without the active ingredient. Neither the participant nor the study doctor will know the treatment each participant is receiving until the study is completed. All enrolled participants will place 1 drop of CA201A four times daily, starting 7 days prior to the surgery, continue on the day of surgery, and then keep using them for 4 weeks following surgery. After treatment, participants will be followed for up to 12 weeks after surgery in order to monitor safety and assess how well the treatment works. All participants will undergo standard cataract surgery and receive usual care; the study eye drops will be given in addition to this routine treatment. Throughout the study, doctors will measure changes in corneal endothelial cell density and perform other eye examinations to evaluate the treatment effect.

Participants needed: 200
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: Caravel Oculus Pty LtdUpdated: Aug 6, 2026Locations: 8
Eligibility criteria

The subject must voluntarily sign and date a Human Research Ethics Committee (HR... [+10]

Active immunosuppressive or autoimmune disease that, in the opinion of the Inves... [+29]

Status: Not yet recruiting

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells \[mHCECs\]), compared with a placebo injection, in participants with corneal edema caused by corneal endothelial dysfunction.

Participants needed: 121
Trial details
Phase: Phase 2Age: 21+Biological sex: AllType: InterventionalSponsor: EmmecellUpdated: Jul 29, 2026Locations: 1
Eligibility criteria

Symptomatic central corneal edema that is primarily responsible for loss of visi... [+4]

Corneal disease in either eye (other than corneal endothelial dysfunction second... [+9]

Status: Recruiting

The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study

The purpose of this international cohort study is to validate a new method for preoperative assessment of endothelial viability in donor corneal tissues for transplantation, and to correlate endothelial health as assessed by the surgical team to functional and structural long-term outcomes in the cohort of patients receiving them.

Participants needed: 135
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaUpdated: Oct 2, 2025Locations: 12
Eligibility criteria

Age older than 18 years old [+3]

Prior corneal transplantation [+8]